Previous 10 | Next 10 |
MYOS RENS Technology (NASDAQ: MYOS ) : Q2 GAAP EPS of -$0.07. Revenue of $0.33M (+120.0% Y/Y) Press Release More news on: MYOS RENS Technology Inc., Earnings news and commentary, Healthcare stocks news, ,
CEDAR KNOLLS, N.J. , Aug. 5, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition that helps build lean muscle, announces its results for the ...
MYOS RENS Technology ( MYOS -3.8% ) has settled its pending litigation with RENS Technology and its President, Ren Ren. More news on: MYOS RENS Technology Inc., Healthcare stocks news, Read more ...
AC Immune (NASDAQ: ACIU ) +76% on advancement of Alzheimer's vaccine study. More news on: AC Immune SA, Future FinTech Group Inc., Boxlight Corporation, Stocks on the move, , Read more ...
CEDAR KNOLLS, N.J. , July 16, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle,...
NEW YORK, NY / ACCESSWIRE / July 8, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed t...
NEW YORK , July 8, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City , is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn ...
Nano cap MYOS RENS Technology ( MYOS +8.7% ) is up, albeit on below-average volume, on the heels of a study evaluating the impact of Fortetropin on the rate of muscle protein synthesis in older adults. The data were just published in The Journals of Gerontology Series A. Mor...
Corvus Pharmaceuticals (NASDAQ: CRVS ) +103% on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...
CEDAR KNOLLS, N.J. , July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build ...
News, Short Squeeze, Breakout and More Instantly...
Myos Rens Technology Company Name:
MYOS Stock Symbol:
NASDAQ Market:
MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding PR Newswire CEDAR KNOLLS, N.J., Nov. 17, 2020 CEDAR KNOLLS, N.J. , Nov. 17, 2020 /PRNewswire/ -- MYOS RENS Techno...
MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger PR Newswire CEDAR KNOLLS, N.J., Nov. 12, 2020 CEDAR KNOLLS, N.J. , Nov. 12, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") ...
MYOS RENS Technology Announces Net Revenues Increase 39% for the Three Months Ended September 30, 2020 Net Revenues Increased 16% for the nine months ended September 30, 2020 PR Newswire CEDAR KNOLLS, N.J., Nov. 6, 2020 CEDAR KNOLLS, N.J. , Nov. 6, 2020 /...